CoChat
Sign Up
Cited by 12Cervical Cancer and HPV ResearchDNA Repair MechanismsEndometrial and Cervical Cancer Treatments

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Modulating the DNA Damage Response to Improve Treatment Response in Cervical Cancer

Cossar, L.H., Schache, A.G., Risk, J.M., Sacco, J.J., Jones, N.J., Lord, R.·2017·Clinical Oncology
DOI 10.1016/j.clon.2017.03.002
Open this paper in CoChat — free account

Abstract

Cervical cancer is the fourth most common cause of cancer-related death in women worldwide and new therapeutic approaches are needed to improve clinical outcomes for this group of patients. Current treatment protocols for locally advanced and metastatic disease consist of ionising radiation and chemotherapy. Chemoradiation induces cytotoxic levels of DNA double-strand breaks, which activates programmed cell death via the DNA damage response (DDR). Cervical cancers are unique given an almost exclusive association with human papillomavirus (HPV) infection; a potent manipulator of the DDR, with the potential to alter tumour sensitivity to DNA-damaging agents and influence treatment response. This review highlights the wide range of therapeutic strategies in development that have the potential to modulate DDR and sensitise cervical tumours to DNA-damaging agents in the context of HPV oncogenesis.

Overview

Integrity signals

Registry

Crossref · 10.1016/j.clon.2017.03.002

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 3 references

Research works printed but not linked: 88

  1. Jemal, 2011, Global cancer statistics, CA: Cancer J Clin, 61, 69
  2. Vale, 2010, Substantial improvement in UK cervical cancer survival with chemoradiotherapy: results of a Royal College of Radiologists' audit, Clin Oncol, 22, 590, 10.1016/j.clon.2010.06.002 · DOI
  3. Monk, 2009, Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study, J Clin Oncol, 27, 4649, 10.1200/JCO.2009.21.8909 · DOI
  4. Tewari, 2014, Improved survival with bevacizumab in advanced cervical cancer, New Engl J Med, 370, 734, 10.1056/NEJMoa1309748 · DOI
  5. Matt, 2016, The DNA damage-induced cell death response: a roadmap to kill cancer cells, Cell Mol Life Sci, 73, 2829, 10.1007/s00018-016-2130-4 · DOI
  6. Gillison, 2014, Eurogin Roadmap: comparative epidemiology of HPV infection and associated cancers of the head and neck and cervix, Int J Cancer, 134, 497, 10.1002/ijc.28201 · DOI
  7. McKinney, 2015, The role of the DNA damage response throughout the papillomavirus life cycle, Viruses, 7, 2450, 10.3390/v7052450 · DOI
  8. Wallace, 2014, Manipulation of cellular DNA damage repair machinery facilitates propagation of human papillomaviruses, Semin Cancer Biol, 26, 30, 10.1016/j.semcancer.2013.12.003 · DOI
  9. Xue, 2015, HPV16-E2 induces prophase arrest and activates the cellular DNA damage response in vitro and in precursor lesions of cervical carcinoma, Oncotarget, 6, 34979, 10.18632/oncotarget.5512 · DOI
  10. Ojesina, 2014, Landscape of genomic alterations in cervical carcinomas, Nature, 506, 371, 10.1038/nature12881 · DOI
  11. Park, 2014, Human papillomavirus type 16 E7 oncoprotein causes a delay in repair of DNA damage, Radiother Oncol, 113, 337, 10.1016/j.radonc.2014.08.026 · DOI
  12. Song, 1998, Human papillomavirus type 16 E6 and E7 oncogenes abrogate radiation-induced DNA damage responses in vivo through p53-dependent and p53-independent pathways, Proc Natl Acad Sci USA, 95, 2290, 10.1073/pnas.95.5.2290 · DOI
  13. Rieckmann, 2013, HNSCC cell lines positive for HPV and p16 possess higher cellular radiosensitivity due to an impaired DSB repair capacity, Radiother Oncol, 107, 242, 10.1016/j.radonc.2013.03.013 · DOI
  14. Lindel, 2005, Human papillomavirus status in advanced cervical cancer: predictive and prognostic significance for curative radiation treatment, Int J Gynecol Cancer, 15, 278, 10.1136/ijgc-00009577-200503000-00015 · DOI
  15. Goodarzi, 2013, The repair and signaling responses to DNA double-strand breaks, Adv Genet, 82, 1, 10.1016/B978-0-12-407676-1.00001-9 · DOI
  16. Chapman, 2012, Playing the end game: DNA double-strand break repair pathway choice, Mol Cell, 47, 497, 10.1016/j.molcel.2012.07.029 · DOI
  17. Brown, 2015, Ubiquitylation, neddylation and the DNA damage response, Open Biol, 5, 150018, 10.1098/rsob.150018 · DOI
  18. Awasthi, 2015, ATM and ATR signaling at a glance, J Cell Sci, 128, 4255
  19. Moody, 2009, Human papillomaviruses activate the ATM DNA damage pathway for viral genome amplification upon differentiation, PLoS Pathogens, 5, e1000605, 10.1371/journal.ppat.1000605 · DOI
  20. Roossink, 2012, The role of ATM and 53BP1 as predictive markers in cervical cancer, Int J Cancer, 131, 2056, 10.1002/ijc.27488 · DOI
  21. Roychowdhury, 2017, Integrative genomic and network analysis identified novel genes associated with the development of advanced cervical squamous cell carcinoma, Biochim Biophys Acta, 1861, 2899, 10.1016/j.bbagen.2016.09.014 · DOI
  22. Price, 1996, The phosphatidylinositol 3-kinase inhibitor wortmannin sensitizes murine fibroblasts and human tumor cells to radiation and blocks induction of p53 following DNA damage, Cancer Res, 56, 246
  23. Li, 2006, Enhanced radiation-mediated cell killing of human cervical cancer cells by small interference RNA silencing of ataxia telangiectasia-mutated protein, Int J Gynecol Cancer, 16, 1620, 10.1136/ijgc-00009577-200607000-00021 · DOI
  24. Tian, 2007, The relationship between the down-regulation of DNA-PKcs or Ku70 and the chemosensitization in human cervical carcinoma cell line HeLa, Oncol Rep, 18, 927
  25. Teng, 2015, Pharmacologic inhibition of ATR and ATM offers clinically important distinctions to enhancing platinum or radiation response in ovarian, endometrial, and cervical cancer cells, Gynecol Oncol, 136, 554, 10.1016/j.ygyno.2014.12.035 · DOI
  26. Wieringa, 2016, Breaking the DNA damage response to improve cervical cancer treatment, Cancer Treat Rev, 42, 30, 10.1016/j.ctrv.2015.11.008 · DOI
  27. Charrier, 2011, Discovery of potent and selective inhibitors of ataxia telangiectasia mutated and Rad3 related (ATR) protein kinase as potential anticancer agents, J Med Chem, 54, 2320, 10.1021/jm101488z · DOI
  28. Hong, 2016, Phase I study of LY2606368, a checkpoint kinase 1 inhibitor, in patients with advanced cancer, J Clin Oncol, 34, 1764, 10.1200/JCO.2015.64.5788 · DOI
  29. Beskow, 2009, Radioresistant cervical cancer shows upregulation of the NHEJ proteins DNA-PKcs, Ku70 and Ku86, Br J Cancer, 101, 816, 10.1038/sj.bjc.6605201 · DOI
  30. Fuhrman, 2008, Radiosensitization of cervical cancer cells via double-strand DNA break repair inhibition, Gynecol Oncol, 110, 93, 10.1016/j.ygyno.2007.08.073 · DOI
  31. van Oorschot, 2016, Targeting DNA double strand break repair with hyperthermia and DNA-PKCS inhibition to enhance the effect of radiation treatment, Oncotarget, 7, 65504, 10.18632/oncotarget.11798 · DOI
  32. Vavrova, 2016, Comparison of the radiosensitizing effect of ATR, ATM and DNA-PK kinase inhibitors on cervical carcinoma cells, Folia Biol, 62, 167, 10.14712/fb2016062040167 · DOI
  33. Scott, 2015, Poly (ADP-ribose) polymerase inhibitors: recent advances and future development, J Clin Oncol, 33, 1397, 10.1200/JCO.2014.58.8848 · DOI
  34. Narayan, 2004, Promoter hypermethylation of FANCF: disruption of Fanconi anemia-BRCA pathway in cervical cancer, Cancer Res, 64, 2994, 10.1158/0008-5472.CAN-04-0245 · DOI
  35. Narayan, 2003, Frequent promoter methylation of CDH1, DAPK, RARB, and HIC1 genes in carcinoma of cervix uteri: its relationship to clinical outcome, Mol Cancer, 2, 24, 10.1186/1476-4598-2-24 · DOI
  36. Price, 2013, Chromatin remodeling at DNA double-strand breaks, Cell, 152, 1344, 10.1016/j.cell.2013.02.011 · DOI · Paper page
  37. Hegan, 2010, Inhibition of poly(ADP-ribose) polymerase down-regulates BRCA1 and RAD51 in a pathway mediated by E2F4 and p130, Proc Natl Acad Sci USA, 107, 2201, 10.1073/pnas.0904783107 · DOI
  38. Hassumi-Fukasawa, 2012, Expression of BAG-1 and PARP-1 in precursor lesions and invasive cervical cancer associated with human papillomavirus (HPV), Pathol Oncol Res, 18, 929, 10.1007/s12253-012-9523-y · DOI
  39. Shunkwiler, 2013, Inhibition of poly(ADP-ribose) polymerase enhances radiochemosensitivity in cancers proficient in DNA double-strand break repair, Int J Mol Sci, 14, 3773, 10.3390/ijms14023773 · DOI
  40. Powell, 2010, Pre-clinical and clinical evaluation of PARP inhibitors as tumour-specific radiosensitisers, Cancer Treat Rev, 36, 566, 10.1016/j.ctrv.2010.03.003 · DOI
  41. Kelland, 1989, The effect of 3-aminobenzamide in the radiation response of three human cervix carcinoma xenografts, Radiother Oncol, 15, 363, 10.1016/0167-8140(89)90083-2 · DOI
  42. Kunos, 2015, A phase I-II evaluation of veliparib (NSC #737664), topotecan, and filgrastim or pegfilgrastim in the treatment of persistent or recurrent carcinoma of the uterine cervix: an NRG Oncology/Gynecologic Oncology Group study, Int J Gynecol Cancer, 25, 484, 10.1097/IGC.0000000000000380 · DOI
  43. Symonds, 2015, Cediranib combined with carboplatin and paclitaxel in patients with metastatic or recurrent cervical cancer (CIRCCa): a randomised, double-blind, placebo-controlled phase 2 trial, Lancet Oncol, 16, 1515, 10.1016/S1470-2045(15)00220-X · DOI
  44. Nogueira-Rodrigues, 2014, Phase 2 trial of erlotinib combined with cisplatin and radiotherapy in patients with locally advanced cervical cancer, Cancer, 120, 1187, 10.1002/cncr.28471 · DOI
  45. de la Rochefordiere, 2015, PIK3CA pathway mutations predictive of poor response following standard radiochemotherapy +/− cetuximab in cervical cancer patients, Clin Cancer Res, 21, 2530, 10.1158/1078-0432.CCR-14-2368 · DOI
  46. Kurtz, 2009, Cetuximab, topotecan and cisplatin for the treatment of advanced cervical cancer: a phase II GINECO trial, Gynecol Oncol, 113, 16, 10.1016/j.ygyno.2008.12.040 · DOI
  47. Farley, 2011, Phase II study of cisplatin plus cetuximab in advanced, recurrent, and previously treated cancers of the cervix and evaluation of epidermal growth factor receptor immunohistochemical expression: a Gynecologic Oncology Group study, Gynecol Oncol, 121, 303, 10.1016/j.ygyno.2011.01.030 · DOI
  48. Pignata, 2015, MITO (Multicentre Italian Trials in Ovarian cancer): CERV 2 trial – a randomized phase II study of carboplatin and paclitaxel +/− cetuximab, in advanced and/or recurrent cervical cancer, ASCO Meeting Abstracts, 33, 5520
  49. Coronel, 2011, A double-blind, placebo-controlled, randomized phase III trial of chemotherapy plus epigenetic therapy with hydralazine valproate for advanced cervical cancer. Preliminary results, Med Oncol, 28, S540, 10.1007/s12032-010-9700-3 · DOI
  50. Bindra, 2004, Down-regulation of Rad51 and decreased homologous recombination in hypoxic cancer cells, Mol Cell Biol, 24, 8504, 10.1128/MCB.24.19.8504-8518.2004 · DOI
  51. Meyn, 2009, Receptor signaling as a regulatory mechanism of DNA repair, Radiother Oncol, 92, 316, 10.1016/j.radonc.2009.06.031 · DOI
  52. Chen, 2007, The epidermal growth factor receptor: a role in repair of radiation-induced DNA damage, Clin Cancer Res, 13, 6555, 10.1158/1078-0432.CCR-07-1610 · DOI
  53. Dittmann, 2005, Radiation-induced epidermal growth factor receptor nuclear import is linked to activation of DNA-dependent protein kinase, J Biol Chem, 280, 31182, 10.1074/jbc.M506591200 · DOI
  54. Muthusami, 2015, FTS is responsible for radiation-induced nuclear phosphorylation of EGFR and repair of DNA damage in cervical cancer cells, J Cancer Res Clin Oncol, 141, 203, 10.1007/s00432-014-1802-4 · DOI
  55. Kim, 2010, Human papillomavirus type 16 E5 oncoprotein as a new target for cervical cancer treatment, Biochem Pharmacol, 80, 1930, 10.1016/j.bcp.2010.07.013 · DOI
  56. Dittmann, 2005, Inhibition of radiation-induced EGFR nuclear import by C225 (Cetuximab) suppresses DNA-PK activity, Radiother Oncol, 76, 157, 10.1016/j.radonc.2005.06.022 · DOI
  57. Meira, 2009, Combination of cetuximab with chemoradiation, trastuzumab or MAPK inhibitors: mechanisms of sensitisation of cervical cancer cells, Br J Cancer, 101, 782, 10.1038/sj.bjc.6605216 · DOI
  58. Myllynen, 2011, In tumor cells regulation of DNA double strand break repair through EGF receptor involves both NHEJ and HR and is independent of p53 and K-Ras status, Radiother Oncol, 101, 147, 10.1016/j.radonc.2011.05.046 · DOI
  59. Cetina, 2015, A pilot study of nimotuzumab plus single agent chemotherapy as second- or third-line treatment or more in patients with recurrent, persistent or metastatic cervical cancer, Cancer Biol Ther, 16, 684, 10.1080/15384047.2015.1026483 · DOI
  60. Murakawa, 2007, Inhibitors of the proteasome suppress homologous DNA recombination in mammalian cells, Cancer Res, 67, 8536, 10.1158/0008-5472.CAN-07-1166 · DOI
  61. Jacquemont, 2007, Proteasome function is required for DNA damage response and Fanconi anemia pathway activation, Cancer Res, 67, 7395, 10.1158/0008-5472.CAN-07-1015 · DOI
  62. Koltai, 2015, Nelfinavir and other protease inhibitors in cancer: mechanisms involved in anticancer activity, F1000Res, 4, 9, 10.12688/f1000research.5827.2 · DOI
  63. Motegi, 2009, The vital link between the ubiquitin-proteasome pathway and DNA repair: impact on cancer therapy, Cancer Lett, 283, 1, 10.1016/j.canlet.2008.12.030 · DOI
  64. Miyamoto, 2013, Sequential effects of the proteasome inhibitor bortezomib and chemotherapeutic agents in uterine cervical cancer cell lines, Oncol Rep, 29, 51, 10.3892/or.2012.2072 · DOI
  65. Lin, 2009, Combination of proteasome and HDAC inhibitors for uterine cervical cancer treatment, Clin Cancer Res, 15, 570, 10.1158/1078-0432.CCR-08-1813 · DOI
  66. Cui, 2015, Bortezomib enhances the radiosensitivity of hypoxic cervical cancer cells by inhibiting HIF-1alpha expression, Int J Clin Exp Pathol, 8, 9032
  67. Matsumoto, 2016, Enhanced efficacy against cervical carcinomas through polymeric micelles physically incorporating the proteasome inhibitor MG132, Cancer Sci, 107, 773, 10.1111/cas.12926 · DOI
  68. Gong, 2013, Mammalian DNA repair: HATs and HDACs make their mark through histone acetylation, Mutat Res, 750, 23, 10.1016/j.mrfmmm.2013.07.002 · DOI
  69. Moody, 2010, Human papillomavirus oncoproteins: pathways to transformation, Nature Rev Cancer, 10, 550, 10.1038/nrc2886 · DOI
  70. Groselj, 2013, Histone deacetylase inhibitors as radiosensitisers: effects on DNA damage signalling and repair, Br J Cancer, 108, 748, 10.1038/bjc.2013.21 · DOI
  71. Fukuda, 2015, Class I histone deacetylase inhibitors inhibit the retention of BRCA1 and 53BP1 at the site of DNA damage, Cancer Sci, 106, 1050, 10.1111/cas.12717 · DOI
  72. Duenas-Gonzalez, 2014, Hydralazine-valproate: a repositioned drug combination for the epigenetic therapy of cancer, Expert Opin Drug Metab Toxicol, 10, 1433, 10.1517/17425255.2014.947263 · DOI
  73. Mani, 2014, Radiosensitization of cervical cancer cells with epigenetic drugs hydralazine and valproate, Eur J Gynaecol Oncol, 35, 140
  74. Chavez-Blanco, 2006, Antineoplastic effects of the DNA methylation inhibitor hydralazine and the histone deacetylase inhibitor valproic acid in cancer cell lines, Cancer Cell Int, 6, 2, 10.1186/1475-2867-6-2 · DOI
  75. De la Cruz-Hernandez, 2011, Transcriptional changes induced by epigenetic therapy with hydralazine and magnesium valproate in cervical carcinoma, Oncol Rep, 25, 399
  76. de la Cruz-Hernandez, 2007, The effects of DNA methylation and histone deacetylase inhibitors on human papillomavirus early gene expression in cervical cancer, an in vitro and clinical study, Virol J, 4, 18, 10.1186/1743-422X-4-18 · DOI
  77. Bisht, 2003, Geldanamycin and 17-allylamino-17-demethoxygeldanamycin potentiate the in vitro and in vivo radiation response of cervical tumor cells via the heat shock protein 90-mediated intracellular signaling and cytotoxicity, Cancer Res, 63, 8984
  78. Candelaria, 2010, Epigenetic therapy and cisplatin chemoradiation in FIGO stage IIIB cervical cancer, Eur J Gynaecol Oncol, 31, 386
  79. Schwock, 2008, Efficacy of Hsp90 inhibition for induction of apoptosis and inhibition of growth in cervical carcinoma cells in vitro and in vivo, Cancer Chemother Pharmacol, 61, 669, 10.1007/s00280-007-0522-8 · DOI
  80. Ha, 2011, Hsp90 inhibitor-mediated disruption of chaperone association of ATR with hsp90 sensitizes cancer cells to DNA damage, Mol Cancer Ther, 10, 1194, 10.1158/1535-7163.MCT-11-0094 · DOI
  81. Dote, 2006, Inhibition of hsp90 compromises the DNA damage response to radiation, Cancer Res, 66, 9211, 10.1158/0008-5472.CAN-06-2181 · DOI
  82. Kolberg, 2004, Structure, function, and mechanism of ribonucleotide reductases, Biochim Biophys Acta, 1699, 1, 10.1016/S1570-9639(04)00054-8 · DOI
  83. Kunos, 2009, Modulating radiation resistance by inhibiting ribonucleotide reductase in cancers with virally or mutationally silenced p53 protein, Radiat Res, 172, 666, 10.1667/RR1858.1 · DOI
  84. Kunos, 2012, Elevated ribonucleotide reductase levels associate with suppressed radiochemotherapy response in human cervical cancers, Int J Gynecol Cancer, 22, 1463, 10.1097/IGC.0b013e318270577f · DOI
  85. Kunos, 2010, Ribonucleotide reductase inhibition enhances chemoradiosensitivity of human cervical cancers, Radiat Res, 174, 574, 10.1667/RR2273.1 · DOI
  86. Kunos, 2013, Radiochemotherapy plus 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) in advanced-stage cervical and vaginal cancers, Gynecol Oncol, 130, 75, 10.1016/j.ygyno.2013.04.019 · DOI
  87. Kunos, 2014, Long-term disease control with triapine-based radiochemotherapy for patients with stage IB2-IIIB cervical cancer, Frontiers Oncol, 4, 184, 10.3389/fonc.2014.00184 · DOI
  88. Sagae, 2016, Advances and concepts in cervical cancer trials: a road map for the future, Int J Gynecol Cancer, 26, 199, 10.1097/IGC.0000000000000587 · DOI

Cited by

Sorted by citations

Metadata

Authors
Cossar, L. H., Schache, A. G., Risk, J. M., Sacco, J. J., Jones, N. J., & Lord, R.
Affiliations
  • University of Liverpool (GB)
  • Clatterbridge Cancer Centre NHS Foundation Trust (GB)
Corresponding author
Cossar, L.H.
ORCID
Venue
Clinical Oncology
Publisher
Elsevier BV
Published
2017-09
Volume
29
Issue
9
Pages
626-634
ISSN
0936-6555 (ISSN-L)
DOI
10.1016/j.clon.2017.03.002
OpenAlex
W2599052812
Cited by
12
References
3
Citations by year
2026: 1 · 2025: 1 · 2024: 1 · 2022: 1 · 2021: 2 · 2019: 2 · 2018: 3 · 2017: 1
FWCI
0.22
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Clinical Oncology (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Clatterbridge Cancer Centre
  • University of Liverpool
Topics
  • Health Sciences › Medicine › Epidemiology › Cervical Cancer and HPV Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA Repair Mechanisms
  • Health Sciences › Medicine › Obstetrics and Gynecology › Endometrial and Cervical Cancer Treatments
Keywords
cervical cancer, DNA damage response, human papillomavirus, chemoradiotherapy, DNA double-strand breaks, radiosensitization, chemosensitization, HPV oncogenesis, treatment response
MeSH terms
Uterine Cervical Neoplasms, DNA Damage, Female, Humans, Papillomavirus Infections

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review